We are excited to announce Ben Gonzales, MBA, as Head of Sales, North America. Ben comes with a history of life science and proteomics commercial development and a track record of successfully growing products and services business. In this position, Ben will be responsible for making Biognosys' services more widely adopted by biopharma researchers and proteomics experts in North America.

The future of personalized medicine relies on the power of multi-omics. Unprecedented reproducibility, sensitivity, throughput, and clinical transferability puts proteomics in a prime position to drive forward the discovery of novel, biologically relevant biomarkers that will transform diagnosis and treatment for a vast range of health conditions in the future.

Mass spectrometry is a powerful and reliable technique that allows for a complete overview of different dimensions of biological insights. Discover more about how mass spectrometry compares to affinity-based proteomics approaches.